Free tool
FAERS Monitor: Tobi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050753 or its brand name (Tobi, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
17,580
Serious
14,064
80% of reports
Hospitalization
8,271
Death reported
2,372
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,343
- infective pulmonary exacerbation of cystic fibrosis1,134
- pneumonia1,109
- dyspnoea1,049
- off label use1,044
- cystic fibrosis830
- cough813
- drug ineffective781
- acute kidney injury712
- infection675
- condition aggravated639
- hospitalisation604
- pyrexia572
- fatigue514
- malaise472
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 92 |
| 2005 | 113 |
| 2006 | 92 |
| 2007 | 146 |
| 2008 | 117 |
| 2009 | 132 |
| 2010 | 193 |
| 2011 | 716 |
| 2012 | 685 |
| 2013 | 720 |
| 2014 | 786 |
| 2015 | 1,157 |
| 2016 | 847 |
| 2017 | 895 |
| 2018 | 1,449 |
| 2019 | 2,047 |
| 2020 | 1,652 |
| 2021 | 1,110 |
| 2022 | 1,045 |
| 2023 | 881 |
| 2024 | 1,079 |
| 2025 | 937 |
| 2026 | 689 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,579 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 1,134 | 314.5 | 295.1 | 280,483 |
| cystic fibrosisSignal | 830 | 210.8 | 196.1 | 147,198 |
| infectionSignal | 675 | 5.6 | 5.2 | 2,552 |
| acute kidney injurySignal | 712 | 5.6 | 5.2 | 2,684 |
| hospitalisationSignal | 604 | 4.7 | 4.4 | 1,772 |
| pneumoniaSignal | 1,109 | 4.1 | 3.9 | 2,637 |
| coughSignal | 813 | 3.5 | 3.2 | 1,446 |
| condition aggravatedSignal | 639 | 2.5 | 2.3 | 590 |
| dyspnoeaSignal | 1,049 | 2.2 | 2.1 | 720 |
| pyrexia | 572 | 2.0 | 1.8 | 280 |
| death | 1,343 | 1.9 | 1.8 | 561 |
| off label use | 1,044 | 1.4 | 1.3 | 139 |
| malaise | 472 | 1.3 | 1.2 | 31 |
| fatigue | 514 | 0.8 | 0.7 | 30 |
| drug ineffective | 781 | 0.7 | 0.7 | 99 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.